Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Elevai Labs, Inc. Common Stock(ELAB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ELAB
09/18/2026: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.
Elevai Labs, Inc. is an early-stage biotechnology company focused on developing exosome-based products for the medical aesthetics market. Its strengths include a specialized, science-driven approach to physician-dispensed skincare that differentiates it from general consumer brands. The primary investment story rests on the potential for its proprietary technology to gain wider adoption within dermatology clinics. However, the company faces significant risks, including intense competition from large-scale medical aesthetic firms, limited operational history, and the need for ongoing growth capital. The stock may suit growth-oriented investors with high risk tolerance who are interested in the clinical aesthetics sector and should monitor the company's product adoption rates and commercial scalability closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the medical aesthetics sector. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical product success and revenue scaling signals. |
| Value investor | Weak fit | The company is not currently valued based on traditional value metrics due to its early-stage status. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses on cash preservation. |
| Low-risk investor | Weak fit | Small-cap biotechnology stocks are characterized by high price volatility and operational risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap stocks are subject to sharp price fluctuations based on news and market sentiment. |
| Valuation risk | High | Early-stage biotech valuations are speculative and sensitive to growth milestones. |
| Competition risk (Aesthetic giants) | High | Dominant competitors have more resources for R&D and distribution. |
| Business quality | Medium | The company is a niche player with unproven long-term scalability. |
| Dividend income | Low / none | Capital is strictly directed toward growth and operations. |
| Execution risk | High | Success depends on navigating complex regulatory and medical adoption hurdles. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.82M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 53.1K shares | Beta -0.3 | 52 Weeks Range 4.40 - 2671.20 | Updated Date 09/18/2026 |
52 Weeks Range 4.40 - 2671.20 | Updated Date 09/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1811.77 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Physician-dispensed Skincare | Direct sales of E-Series and Hair health products to clinics and dermatologists. | The company earns revenue by selling specialized skin care products directly to doctors and clinics. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -692.24K | Price to Sales(TTM) 1.48 |
Enterprise Value -692.24K | Price to Sales(TTM) 1.48 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA - | Shares Outstanding 809.58K | Shares Floating 764.19K |
Shares Outstanding 809.58K | Shares Floating 764.19K | ||
Percent Insiders 5.61 | Percent Institutions 3.29 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Elevai Labs, Inc. Common Stock
Exchange NASDAQ | Headquarters Newport Beach, CA, United States | ||
IPO Launch date 2023-11-21 | CEO, CFO, Secretary & Director Mr. Graydon Bensler C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://pmgcholdings.com |
Full time employees 32 | Website https://pmgcholdings.com | ||
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.